US Physical Therapy (NYSE:USPH) Bolsa

US Physical Therapy

US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal payment sources for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.

US Physical Therapy Inc

JMP Securities analyst Constantine Davides reiterates US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>) with a Market Outperform and maintains $113 price target.

News

Price Target

Reiteration

Analyst Ratings

USPH

JMP Securities Reiterates Market Outperform on US Physical Therapy, Maintains $113 Price Target

JP Morgan analyst Calvin Sternick maintains US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>) with a Overweight and lowers the price target from $120 to $110.

JP Morgan Maintains Overweight on US Physical Therapy, Lowers Price Target to $110

US Physical Therapy Acquires A Practice With Three Locations In Wyoming, Which Generates ~$4.3M In Annual Revenues

In the latest quarter, 4 analysts provided ratings for US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>), showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $111.5, a high estimate of $120.00, and a low estimate of $98.00. This upward trend is apparent, with the current average reflecting a 2.93% increase from the previous average price target of $108.33.
<img src="https://www.benzinga.com/files/images/story/2025/1740747667_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of US Physical Therapy by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$98.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Joanna Gajuk</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$113.00</td>
<td>-</td>
</tr>
<tr>
<td>Calvin Sternick</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$117.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to US Physical Therapy. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of US Physical Therapy compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for US Physical Therapy's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Capture valuable insights into US Physical Therapy's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/USPH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on US Physical Therapy analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind US Physical Therapy</h2>
US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal sources of payment for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.
<h3>Understanding the Numbers: US Physical Therapy's Finances</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: US Physical Therapy's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 12.02%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: US Physical Therapy's net margin is impressive, surpassing industry averages. With a net margin of 3.46%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 1.2%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): US Physical Therapy's ROA stands out, surpassing industry averages. With an impressive ROA of 0.57%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: US Physical Therapy's debt-to-equity ratio is below the industry average at 0.53, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About US Physical Therapy Stock

Barrington Research analyst Michael Petusky maintains US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>) with a Outperform and lowers the price target from $108 to $98.

Barrington Research Maintains Outperform on US Physical Therapy, Lowers Price Target to $98

US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>) reported quarterly earnings of $0.51 per share which missed the analyst consensus estimate of $0.69 by 26.09 percent. This is a 13.56 percent decrease over earnings of $0.59 per share from the same period last year. The company reported quarterly sales of $180.45 million which beat the analyst consensus estimate of $174.77 million by 3.25 percent. This is a 16.57 percent increase over sales of $154.80 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

US Physical Therapy Q4 Adj $0.51 Misses $0.69 Estimate, Sales $180.45M Beat $174.77M Estimate

AAOI

ABEV

ACAD

ACMR

ADTN

ALEC

AMBA

AMBC

AMSF

ARDT

ARHS

ARIS

ARKO

ASTE

ATEC

AVDX

AVNS

BATRA

BATRK

BBSI

BLMN

BXSL

BYND

CAPL

CDNA

CERT

CLDT

CLPT

COCO

COMM

CORT

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRGY

CSAN

CTRI

DHIL

DMRC

DOLE

DORM

EBAY

ECPG

EHTH

ENIC

ENOV

ERII

ESCA

ESTA

EVTC

FTAI

FWRD

GERN

GOGL

GSX Techedu Inc. American Depositary Shares

GOTU

GRBK

HCAT

HNST

IBTA

IMCR

Earnings Scheduled For February 26, 2025

JMP Securities initiated coverage on U.S. Physical Therapy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>), an operator outpatient physical therapy provider with more than 750 owned or managed clinics <a target="_blank" href="https://www.benzinga.com/quote/USPH" rel="noreferrer noopener">across 43 states</a>.
JMP is optimistic about the company&#8217;s unique, partnership-focused outpatient platform. Combined with its pricing strategy, acquisition capabilities, and industrial injury prevention business, it can sustain the company&#8217;s strong revenue growth, averaging 10% annually from 2021 to 2024.
The analyst has initiated with a Market Outperform rating and a <a target="_blank" href="https://www.benzinga.com/quote/USPH/analyst-ratings" rel="noreferrer noopener">price target of $113</a>.
The analyst views U.S. Physical Therapy as a well-run company and a strong player in the physical therapy sector. Its unique partnership model aligns the company&#8217;s goals with its clinic partners, helping to drive growth through new clinic openings. Additionally, U.S. Physical Therapy&#8217;s expanding focus on workplace injury prevention offers a higher-margin, cost-efficient service.
While challenges like rising labor costs and Medicare reimbursement cuts persist, JMP remains optimistic about U.S. Physical Therapy&#8217;s growth potential in 2025-2026, supported by strategic acquisitions and rate negotiations.
Notably, 2025 marks the end of a five-year Medicare rate reduction plan that began in 2021. Though not factored in, any rate improvements or positive changes to Medicare rates or policies could further boost growth projections.
JMP estimates that the U.S. rehabilitation market is worth nearly $40 billion, with over 300 million physical therapy visits yearly.
The physical therapy market is highly competitive and fragmented. There are over 37,000 clinics nationwide, and no single provider holds more than 5% of the market share.
ATI Physical Therapy (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ATIP#OTC">ATIP</a>) is the only other publicly traded pure-play physical therapy company. Select Medical Holdings Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>), a diversified healthcare services provider, also competes in this space through its Outpatient Rehabilitation segment, alongside its operations in long-term acute care hospitals and inpatient rehab facilities. Many of the largest physical therapy providers carry significant debt, which may limit their ability to pursue major acquisitions.
Price Action: USPH stock is trading down by 2.40% at $93.27 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42515091/home-based-health-service-provider-addus-homecare-is-well-positioned-to-grow-analyst" target="_blank" rel="noreferrer noopener">As US Faces Shortage Of Expensive Skilled Clinicians, Home-Based Health Service Provider Addus HomeCare Is Well-Positioned To Grow: Analyst</a></li>
</ul>
Image via Shutterstock.

Analyst Color

Equities

Health Care

Initiation

General

ATIP

US Physical Therapy Positioned For Success Despite Medicare Challenges, Analyst Optimistic On Unique Growth Strategy

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Goldman Sachs analyst Eric Sheridan initiated coverage on Grindr Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRND#NYSE">GRND</a>) with a Buy rating and announced a price target of $20. Grindr shares closed at $15.74 on Friday. See how other analysts view this stock.</li>
<li>JMP Securities analyst Constantine Davides initiated coverage on Addus HomeCare Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) with a Market Outperform rating and announced a price target of $150. Addus HomeCare shares closed at $125.00 on Friday. <a href="https://www.benzinga.com/quote/ADUS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Matthew Caufield initiated coverage on Zenas BioPharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBIO#NASDAQ">ZBIO</a>) with a Buy rating and announced a price target of $30. Zenas BioPharma shares closed at $8.92 on Friday. <a href="https://www.benzinga.com/quote/ZBIO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JMP Securities analyst Constantine Davides initiated coverage on U.S. Physical Therapy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>) with a Market Outperform rating and announced a price target of $113. US Physical Therapy shares closed at $93.46 on Friday. See how other analysts view this stock.</li>
<li>Jones Trading analyst Justin Walsh initiated coverage on Alto Neuroscience, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANRO#NYSE">ANRO</a>) with a Buy rating and announced a price target of $18. Alto Neuroscience shares closed at $3.83 on Friday. <a href="https://www.benzinga.com/quote/ANRO/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ADUS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="628" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16075847/image-125-1024x628.png" alt="" class="wp-image-693734" style="width:595px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16075847/image-125-1024x628.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16075847/image-125-300x184.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16075847/image-125-768x471.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16075847/image-125.png 1118w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks With Over 6% Dividend Yields

Pre-Market Outlook

Markets

Trading Ideas

ADUS

ANRO

GRND

ZBIO

This Addus HomeCare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

B of A Securities analyst Joanna Gajuk upgrades US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>) from Neutral to Buy and raises the price target from $100 to $115.

Upgrades

B of A Securities Upgrades US Physical Therapy to Buy, Raises Price Target to $115

JMP Securities analyst Constantine Davides initiates coverage on US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>) with a Market Outperform rating and announces Price Target of $113.

JMP Securities Initiates Coverage On US Physical Therapy with Market Outperform Rating, Announces Price Target of $113

During the last three months, 6 analysts shared their evaluations of US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $107.0, with a high estimate of $120.00 and a low estimate of $90.00. A 3.17% drop is evident in the current average compared to the previous average price target of $110.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1733248825_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of US Physical Therapy by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calvin Sternick</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$108.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$108.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$108.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Joanna Gajuk</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$108.00</td>
<td>$108.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to US Physical Therapy. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of US Physical Therapy compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into US Physical Therapy's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/USPH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on US Physical Therapy analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering US Physical Therapy: A Closer Look</h2>
US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal sources of payment for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.
<h3>Unraveling the Financial Story of US Physical Therapy</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: US Physical Therapy's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 12.02%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: US Physical Therapy's net margin excels beyond industry benchmarks, reaching 3.46%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): US Physical Therapy's ROE stands out, surpassing industry averages. With an impressive ROE of 1.2%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): US Physical Therapy's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.57% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: US Physical Therapy's debt-to-equity ratio is below the industry average. With a ratio of 0.53, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Unveiling 6 Analyst Insights On US Physical Therapy

JP Morgan analyst Calvin Sternick maintains US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>) with a Overweight and raises the price target from $117 to $120.

JP Morgan Maintains Overweight on US Physical Therapy, Raises Price Target to $120

U.S. Physical Therapy Acquired A 75% Interest In Hand And Physical Therapy Practice With Eight Clinic Locations In Wyoming, With Approximately $6.5M In Annual Revenues And 43,000 In Annual Visits, Current Owners Retain A 25% Ownership Interest

Barrington Research analyst Michael Petusky maintains US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>) with a Outperform and maintains $108 price target.

Barrington Research Maintains Outperform on US Physical Therapy, Maintains $108 Price Target

Revealing a significant insider sell on November 12, Graham Reeve, COO at US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>), as per the latest SEC filing.
What Happened: According to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000885978/000095017024125739//Archives/edgar/data/885978/000095017024125739/0000950170-24-125739-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday, Reeve sold 1,724 shares of US Physical Therapy. The total transaction value is $166,003.
Monitoring the market, US Physical Therapy's shares down by 0.0% at $92.1 during Wednesday's morning.
<h3>Get to Know US Physical Therapy Better</h3>
US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal sources of payment for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.
<h3>Understanding the Numbers: US Physical Therapy's Finances</h3>
Positive Revenue Trend: Examining US Physical Therapy's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 0.5% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 17.34%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): US Physical Therapy's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 0.39.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.53.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: US Physical Therapy's stock is currently priced at a premium level, as reflected in the higher-than-average P/E ratio of 104.66.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 2.15 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): A high EV/EBITDA ratio of 22.77 positions the company as being more valued compared to industry benchmarks.
</li>
</ul>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
Insider transactions should be considered alongside other factors when making investment decisions, as they can offer important insights.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Essential Transaction Codes Unveiled</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000885978">Check Out The Full List Of US Physical Therapy's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

COO Of US Physical Therapy Makes $166K Sale

During the last three months, 5 analysts shared their evaluations of US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>), revealing diverse outlooks from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $104.4, along with a high estimate of $108.00 and a low estimate of $90.00. This current average represents a 6.79% decrease from the previous average price target of $112.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1731006043_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of US Physical Therapy by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$108.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$108.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Joanna Gajuk</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$108.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$108.00</td>
<td>$122.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to US Physical Therapy. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of US Physical Therapy compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of US Physical Therapy's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of US Physical Therapy's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/USPH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on US Physical Therapy analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About US Physical Therapy</h2>
US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal sources of payment for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.
<h3>Unraveling the Financial Story of US Physical Therapy</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: US Physical Therapy's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 10.37%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: US Physical Therapy's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 4.21%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 1.46%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): US Physical Therapy's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.69%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.53.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing US Physical Therapy: Insights From 5 Financial Analysts

WIIM

US Physical Therapy shares are trading higher after the company reported better-than-expected Q3 financial results.

US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>) reported quarterly earnings of $0.69 per share which beat the analyst consensus estimate of $0.68 by 1.47 percent. This is a 11.29 percent increase over earnings of $0.62 per share from the same period last year. The company reported quarterly sales of $168.033 million which beat the analyst consensus estimate of $164.381 million by 2.22 percent. This is a 12.02 percent increase over sales of $150.007 million the same period last year.

US Physical Therapy Q3 2024 Adj. EPS $0.69 Beats $0.68 Estimate, Sales $168.033M Beat $164.381M Estimate

Press Releases

U.S. Physical Therapy Announces Acquisition of 50-Clinic Physical Therapy Management Services Organization

U.S. Physical Therapy, Inc. Schedules Third Quarter 2024 Earnings Release and Conference Call

U.S. Physical Therapy Completes Acquisition of 50-Clinic Physical Therapy Practice

U.S. Physical Therapy Reports Third Quarter 2024 Results

U.S. Physical Therapy to Present at the Stephens Annual Investment Conference and 16th Annual Southwest IDEAS Conference

U.S. Physical Therapy Announces the Acquisition of an Eight-Clinic Hand and Physical Therapy Practice

U.S. Physical Therapy, Inc. Schedules Fourth Quarter and Year Ended December 31, 2024 Earnings Release and Conference Call Dates

U.S. Physical Therapy Reports Fourth Quarter and Full Year 2024 Results

U.S. Physical Therapy Announces the Acquisition of a Three-Clinic Physical Therapy Practice

U.S. Physical Therapy, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call Dates

Comments

US Physical Therapy

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL